株洲旗滨集团股份有限公司 2025 年第五次临时股东会会议资料 株洲旗滨集团股份有限公司 2025 年第五次临时股东会会议资料 （二〇二五年十二月二十九日召开） 二〇二五年十二月 * 为便于材料使用，议程议案等落款日期均使用会议召开当日日期 1 株洲旗滨集团股份有限公司 2025年第五次临时股东会会议资料 网络投票起止时间：自 2025 年 12 月 29 日至 2025 年 12 月 29 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25,9:30-11:30,13:00-15:00；通过互 联网投票平台的投票时间为股东会召开当日的 9:15-15:00。 现场会议地点：公司会议室（具体地址：深圳市南山区桃源街道龙珠四路 2 号方大城 T1 栋 31 楼） 会议方式：现场投票和网络投票相结合的方式 主持人：董事长张柏忠先生 株洲旗滨集团股份有限公司 2025 年第五次临时股东会会议议程 现场会议时间：2025 年 12 月 29 日 14 点 00 分 一、宣读参加股东会现场会议的股东（包括股东代理人）人数、持有和代表 的股份数； 二、 ...

Group 1 - Lu Kang Pharmaceutical plans to increase capital by 109 million yuan to its wholly-owned subsidiary Bio-Pesticide Company and 27 million yuan to Ze Run Company, aiming to expand its pesticide and sales sectors [1] - Hui Green Ecology intends to sell two properties in Ningbo for 12.52 million yuan, expecting a net profit impact of approximately 6.23 million yuan from the transaction [2] - Tianyuan Co., Ltd. plans to invest 185 million yuan in an intelligent upgrade project for its titanium dioxide production facilities [3] Group 2 - Metro Design has received approval from the Shenzhen Stock Exchange for its share issuance to acquire 100% equity of Guangzhou Metro Engineering Consulting Co., Ltd. for 511 million yuan [4] - South Network Energy announced a mid-term profit distribution plan for 2025, proposing a cash dividend of 0.07 yuan per 10 shares [5] - Qibin Group plans to establish two wholly-owned subsidiaries in Shenzhen with a registered capital of 100 million yuan each [6] Group 3 - All New Good received an administrative regulatory decision from the Shenzhen Securities Regulatory Bureau due to issues in financial accounting and information disclosure [7] - Luokai Co., Ltd. announced that its shareholders plan to reduce their holdings by up to 3% of the company's shares [8][9] - Jincheng Pharmaceutical's actual controller received an administrative penalty from the CSRC for stock manipulation, leading to the resignation of the chairman [10] Group 4 - Yicheng New Energy intends to acquire a 7.69% stake in Kaifeng Times for 10 million yuan, enhancing its strategic development [11] - Yujing Co., Ltd. signed a sales contract worth approximately 28.6 million USD with an overseas photovoltaic company [12] - Nuocheng Jianhua's TRK inhibitor, Zoltracitinib, has been approved for market entry in China [13] Group 5 - Nandu Power announced that its controlling shareholder is planning a change in control, leading to a temporary suspension of its stock [14] - Xinxing Casting plans to acquire 100% equity of China Resources Steel for 1.244 billion yuan to focus on special steel development [15] - Xinlitai is planning to issue H-shares and list on the Hong Kong Stock Exchange [16] Group 6 - Blue Fan Medical's subsidiary received approval for a new medical device, the coronary artery scoring balloon dilation catheter [18] - China Iron & Steel plans to establish a joint venture with several companies to provide new energy transportation solutions with a registered capital of 500 million yuan [19] - Jifeng Technology intends to sign a cooperation framework agreement with Dongtai Lianfei for a total transaction amount not exceeding 100 million yuan [20] Group 7 - Zhongwei Electronics announced a change in its actual controller, with stock resuming trading [21] - Weihong Co., Ltd. plans to reduce its holdings by up to 1.15% of the company's shares [22] - Te Fa Information received a criminal judgment related to a fraud case involving the acquisition of Shenzhen Te Fa Dongzhi Technology Co., Ltd. [23] Group 8 - Sunshine Dairy's controlling shareholder's concerted action plans to reduce holdings by up to 3% of the company's shares [24] - Meikailong reported that Taobao Holdings and New Retail Fund collectively reduced their H-shares by 30.616 million shares [25] - Xinjubang plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [26] Group 9 - Beite Technology's application for issuing A-shares to specific objects has been approved by the Shanghai Stock Exchange [28] - Victory Energy's controlling shareholder is planning a change in control, with stock resuming trading [29] - Jiutian Pharmaceutical signed a patent and technology transfer agreement for a small molecule analgesic drug project, with a total transfer fee not exceeding 400 million yuan [29]

关于控股子公司旗滨光能的员工持股平台部分股权转让暨公司 放弃优先购买权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 株洲旗滨集团股份有限公司（以下简称"旗滨集团"或"公司"）控股 子公司湖南旗滨光能科技有限公司（以下简称"旗滨光能"）的少数股东宁海旗 昭新能源科技合伙企业（有限合伙）（以下简称"宁海旗昭"）、宁海旗富企业 管理合伙企业（有限合伙）（以下简称"宁海旗富"）、宁海旗平照明器具合伙 企业（有限合伙）（以下简称"宁海旗平"）、宁海旗进企业管理咨询合伙企业 （有限合伙）（以下简称"宁海旗进"）、宁海旗阳新材料科技合伙企业（有限 合伙）（以下简称"宁海旗阳"）、宁海旗森人力资源管理合伙企业（有限合伙） （以下简称"宁海旗森"）、宁海旗锦市场营销策划合伙企业（有限合伙）（以 下简称"宁海旗锦"）、宁海旗兴玻璃制品合伙企业（有限合伙）（以下简称"宁 海旗兴"）、宁海旗宁销售代理合伙企业（有限合伙）（以下简称"宁海旗宁"）、 宁海旗盈工程管理合伙企业（有限合伙）（以下简称"宁海旗盈"）、宁海旗利 供应链 ...

证券代码：601636 证券简称：旗滨集团 公告编号：2025-132 株洲旗滨集团股份有限公司 关于拟注册和发行超短期融资券及中期票据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步拓宽融资渠道、优化融资结构、增加直接融资比例，根据中国人民 银行《银行间债券市场非金融企业债务融资工具管理办法》的有关规定，结合公 司发展需要，公司拟向中国银行间市场交易商协会申请注册并发行超短期融资券 和中期票据。具体内容如下： 一、本次超短期融资券及中期票据发行方案 1.发行主体：株洲旗滨集团股份有限公司； 2.发行市场：全国银行间债券市场； 6.发行方式：采用簿记建档、集中配售的方式在银行间市场公开发行； 7.发行利率：根据市场利率波动情况择机发行，以获得最优市场利率； 8.发行对象：全国银行间债券市场的机构投资者（国家法律法规禁止的购买 者除外）； 9.还本付息方式：中期票据为每年付息一次；超短期融资券于兑付日一次性 还本付息； 10.承销方式：由主承销商以余额包销的方式承销； 11.资金用途：包括但不限于补充公司流动资金 ...

Core Viewpoint - The company has decided to waive its preferential purchase rights for a 13.75% stake in its subsidiary, Hunan Qibin Optical Technology Co., Ltd., which is to be sold for 473 million yuan to China Orient Asset Management Co., Ltd. This transaction is classified as a related party transaction, and the company aims to introduce strategic partners to enhance the development of Qibin Optical and maximize overall value [1]. Group 1 - The company will transfer a 13.75% stake in Hunan Qibin Optical Technology Co., Ltd. for 473 million yuan [1]. - The transaction is a related party transaction, with the transferor being an enterprise controlled by the company's actual controller [1]. - The company states that waiving the preferential purchase rights is a prudent response to industry adjustments [1]. Group 2 - After the transaction, the company will remain the controlling shareholder of Qibin Optical, with its shareholding ratio unchanged [1].

Core Viewpoint - Qibin Group (601636.SH) announced the transfer of 13.75% equity in its subsidiary Qibin Energy to Dongfang Asset for a total price of 473.45 million yuan, aiming to introduce strategic partners and enhance its development momentum and risk resistance [1]. Group 1 - Qibin Group holds a 71.22% stake in Qibin Energy, while Ninghai Qibin Keyuan Enterprise Management Consulting Partnership (Limited Partnership) owns 13.75%, and 16 employee stockholding platforms collectively hold 15.03% [1]. - The transfer price for the 13.75% equity stake is set at 47,345,000 yuan, which equates to 1.07 yuan per 1 yuan of registered capital [1]. - The company has decided to waive its preferential purchase rights regarding the equity transfer [1].

Core Insights - Company plans to establish a wholly-owned subsidiary, Shenzhen Qibin Technology Development Co., Ltd., with a registered capital of 100 million yuan to streamline its R&D business chain and optimize its R&D system and processes [1][2] - The new subsidiary will serve as the investment entity for setting up another subsidiary, Shenzhen Qibin Technology Co., Ltd., also with a registered capital of 100 million yuan [1][2] Group 1 - The headquarters is located in Shenzhen, leveraging the city's rich technological innovation resources and favorable environment for R&D innovation [2] - Bao'an District in Shenzhen is highlighted as a key area for industrial development, benefiting from multiple strategic opportunities such as the opening of the Shenzhen-Zhongshan Corridor and the integration of the Pearl River Delta [2] - The company aims to establish a "dual platform" (resource platform + strategic investment platform) to enhance its R&D system and management mechanisms [2] Group 2 - Qibin Technology will act as a collaborative platform for external R&D investments, while Qibin Technology Co., Ltd. will manage internal R&D projects, incubation, and technology transfer [2] - The coordinated operation of the "dual platform" is expected to strengthen the company's core competitiveness in R&D innovation and support its long-term development in the high-end glass sector [2]

Core Viewpoint - Qibin Group (601636.SH) announced that its subsidiary, Hunan Qibin Optical Energy Technology Co., Ltd. (referred to as "Qibin Optical Energy"), will transfer 13.75% of its equity held by minority shareholder Ninghai Qibin Keyuan Enterprise Management Consulting Partnership (Limited Partnership) to China Orient Asset Management Co., Ltd. for 47.345 million yuan [1] Group 1 - The initial investment price for the transferred equity was 1.13 yuan per 1 yuan of registered capital, with an initial investment amount of 50 million yuan [1] - The company has decided to waive its right of first refusal on the equity transfer, which is in accordance with the Company Law and the articles of association of Qibin Optical Energy [1] - The transfer involves a related party, as Ninghai Keyuan is controlled by the company's actual controller, Mr. Yu Qibing, but it does not constitute a major asset restructuring as defined by the regulations [1]

董事、高级管理人员持有和买卖公司股票管理制度 第一章 总则 株洲旗滨集团股份有限公司 第一条 为加强对董事、高级管理人员所持本公司股份及其变动的管理，根据 《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以 下简称"《证券法》"）、中国证监会《上市公司董事、高级管理人员所持本公司股份 及其变动管理规则》、《上市公司股东减持股份管理暂行办法》、上海证券交易所《上 海证券交易所股票上市规则》、《上市公司自律监管指引第 8 号-股份变动管理》、《上 市公司自律监管指引第 15 号——股东及董事、高级管理人员减持股份》等相关法 律、法规和《公司章程》的有关规定，结合公司实际情况，制定本制度。 第二条 本制度中"公司"或"本公司"均指株洲旗滨集团股份有限公司。 第三条 本制度适用于本公司的董事、高级管理人员。高级管理人员指公司总 裁、副总裁、财务总监、董事会秘书以及《公司章程》及董事会认定的其他人员。 第四条 董事、高级管理人员所持本公司股份，是指登记在其名下和利用他人 账户持有的所有本公司股份。董事、高级管理人员从事融资融券交易的，其所持本 公司股份还包括在其信用账户内的本公司股份，股份 ...

株洲旗滨集团股份有限公司 董事会治理及人力委员会实施细则 第一章 总则 第一条 为完善株洲旗滨集团股份有限公司（以下简称"公司"）法人治理结 构，优化公司董事会和经理层的治理关系和合规高效运作，促使董事会提名、任免 董事、高级管理人员的程序更加科学和民主，公司董事会下设董事会治理及人力委 员会作为专门机构，主要负责对公司董事、高级管理人员的提名、任免、选任标准 和程序、绩效评估、薪酬方案及考核、组织治理、业务合规等事项进行研究并提出 建议。 第二条 为规范、高效地开展工作，公司董事会根据《中华人民共和国公司法》 （以下简称"《公司法》"）《上市公司治理准则》《上市公司独立董事管理办法》 等有关法律、法规和规范性文件及《株洲旗滨集团股份有限公司章程》（以下简称 "《公司章程》"）的有关规定，制定本细则。 第三条 治理及人力委员会所作决议，应当符合有关法律、法规、规范性文件 及《公司章程》、本细则的规定。治理及人力委员会决议内容违反有关法律、法规 或《公司章程》、本细则的规定的，该项决议无效。治理及人力委员会决策程序违 反有关法律、法规或《公司章程》、本细则的规定的，自该决议作出之日起 60 日 内，有关利害关系 ...